App-Quantinova.ai

Impact of mepolizumab on work productivity and activity impairment in severe eosinophilic asthma

Necdet B Gunsoy - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Mepolizumab

A study to define microbiome subtypes in the adult asthmatic airway

Ashley Sullivan - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Exercise and diet improve asthma controlin non-obese asthma patients - a randomised controlled trial

Louise Toennesen - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Nitric oxide

Chronic cough: objective cough frequency in a large cough clinic cohort

Hannah Fletcher - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Mepolizumab improves activity limitation in severe eosinophilic asthma

Frank Albers - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Mepolizumab

Blood eosinophil (EOS) count, exacerbation rate and response to roflumilast in patients with severe COPD

Fernando J. Martinez - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

roflumilast

Using Gold Standard Framework Criteria in COPD: Empowering Patients to make Choices about End of Life Care

Sharada Gudur - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Mortality after an acute exacerbation of COPD (AECOPD): findings from the National COPD Audit Programme

Robert Stone - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

MISSION COPD: A novel model of integrated multidisciplinary COPD care that demonstrates significant reductions in unscheduled health care usage

Eleanor Lanning - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

A real world experience of COPD exacerbations and possible association with Bronchiectasis in a medium size teaching hospital in the northwest of England

Himanshu Singh - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Assessing E-RS to measure symptoms in COPD patients with a reversible component

Linda Nelsen - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

Salbutamol

Classifying patients as GOLD A–D using the 2017 strategy criteria: impact on efficacy by GOLD stage in the OTEMTO tiotropium+olodaterol clinical trials

Dave Singh - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Tiotropium/olodaterol

Efficacy of aclidinium/formoterol: pooled post hoc analysis of patients naïve to COPD maintenance therapy

Dave Singh - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

LAS 34273

Development of a COPD model of care in a rural District General Hospital in Highland Scotland

Lorna Murray - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study (Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine)

Roberto Walter Dal Negro - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Erdosteine

Treatment of COPD Exacerbation in Switzerland - results and recommendations of the European COPD Audit

Desiree Schumann - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Impact of grouping patients by 2017 GOLD strategy assessment criteria: a post hoc analysis of the TONADO and OTEMTO trials

Roland Buhl - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Tiotropium bromide

Increased expression of Lysosomal-associated membrane protein 1 (LAMP-1) found in small airway epithelium of COPD may have functional consequence and role in autophagy

Mathew Eapen - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Serum Levels of Club-Cell Protein 16 (CC-16), Surfactant Protein D (SPD), soluble Receptor of Glycation End-products (sRAGE), Fibrinogen and C-Reactive Protein (CRP) and FEV1 Decline, Exacerbations and Mortality in SUMMIT

Bartolome R. Celli - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Fluticasone furoate

A method for calculation of arterial blood gas values from measurements in the peripheral blood (v-TAC): The first UK study

Ari Manuel - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Filters

45280 Abstracts